Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics (Nasdaq: PSTV) will rebrand as Cerenome and begin trading as CNSY on August 3, 2026, while affirming 2026 milestone guidance.
Key updates include REYOBIQ trial and manufacturing progress, rapid CNSide payer and test-volume growth, Medicare enrollment, a new PLA billing code, and an AI/data partnership with Ephemeral Technologies.
Plus Therapeutics (Nasdaq:PSTV) subsidiary CNSide Diagnostics signed a national agreement with Elevance Health, effective May 1, 2026, adding coverage for about 45.4 million people and raising total CNSide® CSF TCE assay contracted coverage to 126 million.
The CNSide® platform supports diagnosis and management of leptomeningeal metastases, with over 11,000 tests run at more than 120 U.S. cancer institutions since 2020. Reported performance includes 92% sensitivity, 95% specificity, and influence on treatment decisions in 90% of cases, supported by 9 peer-reviewed publications and the FORESEE clinical trial.
Plus Therapeutics (Nasdaq:PSTV) will host a business update conference call and webcast on June 30, 2026 at 8:30 a.m. ET. Management plans to discuss the CNSide® diagnostic launch, the integrated development plan for lead drug Reyobiq, CNS oncology strategy, and native artificial intelligence initiatives.
Plus Therapeutics (Nasdaq:PSTV) announced that its wholly owned subsidiary CNSide Diagnostics has received CAP accreditation for its Houston clinical laboratory, complementing existing CLIA certification.
The accreditation is expected to support U.S. commercialization of the CNSide® CSF Assay Platform, payor engagement, health system adoption, and future test menu expansion.
Plus (Nasdaq:PSTV) reported new health economics data for its CNSide CSF assay in leptomeningeal metastases (LM). The cost-of-care analysis, co-authored with Harvard, suggests earlier LM detection and optimized treatment enabled by CNSide may cut LM-related healthcare costs by ~33–47%.
The study cites median inpatient admissions of about $20,000 and total LM-related costs potentially exceeding $100,000 per month. The poster received Blue Ribbon recognition at the ISPOR 2026 Annual Meeting as Plus advances U.S. commercialization supported by recent payer agreements.
Plus Therapeutics (Nasdaq:PSTV) signed a strategic partnership with Ephemeral Technologies to deploy an AI-native platform for CNS oncology. The platform will integrate Plus’ therapeutic, diagnostic, and bioinformatics data to derive actionable intelligence and support precision neuro-oncology initiatives and operational workflows from 2026 onward.
Plus Therapeutics (Nasdaq:PSTV) reported Q1 2026 results and key milestones for its REYOBIQ clinical program and CNSide commercial rollout.
Q1 revenue was $1.0M, operating loss $7.1M, net loss $6.9M ($1.05/share), and cash/investments $15.1M after a $15M upsized offering.
Highlights include FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, a Category III CPT code for REYOBIQ delivery, expanded CNSide payer coverage to about 81M lives, Medicare enrollment and a unique PLA code for CNSide, and a second GMP manufacturing site for REYOBIQ. The company reaffirmed 2026 milestones for Phase 2/Phase 1 trials, commercial manufacturing scale-up, and CNSide test and coverage targets.
Plus Therapeutics (NASDAQ: PSTV) reported an oral plenary presentation at AANS (May 1-4, 2026) reviewing clinical and translational data for REYOBIQ (rhenium Re186 obisbemeda) in leptomeningeal metastases (LM).
Key points: Phase 1 ReSPECT-LM showed median overall survival ~9 months at the recommended Phase 2 dose versus historical ~2–6 months; robust circulating tumor cell reductions; favorable safety; target-to-off-target dose ratio >100:1. A multiple-dose Phase 1 trial is currently enrolling at UT Health San Antonio.
Plus Therapeutics (Nasdaq: PSTV) announced that subsidiary CNSide Diagnostics is enrolled in Medicare and received a Provider Transaction Access Number (PTAN), establishing the lab as Medicare‑enrolled for the CNSide® CSF Assay Platform including the tumor cell enumeration (TCE) test. Claims will be reimbursed if deemed reasonable and necessary by the local Medicare Administrative Contractor.
The company cited a pathway to ~35 million Medicare Advantage beneficiaries, existing ~81 million commercial covered lives, and a target of 150 million+ covered lives in 2026. A new CPT code 0640U is effective for billing July 1, 2026, with pricing via crosswalk or gapfill.
Plus Therapeutics (Nasdaq: PSTV) announced that Blue Shield of California will provide reimbursement for the CNSide® CSF Tumor Cell Enumeration assay, effective April 2026, expanding covered lives from ~75 million to ~81 million (+6 million).
The coverage aims to reduce reimbursement barriers, accelerate adoption across oncology centers, and advance the company’s 2026 objective of 150 million covered lives. CNSide reports >11,000 tests since 2020, sensitivity 92%, specificity 95%, and treatment decisions influenced in 90% of cases. Health economic analyses cited ~40% reduction in leptomeningeal metastases-related costs.